Home » Newsletters » BioWorld Science

BioWorld Science

April 29, 2020

View Archived Issues

Oral drug can wake up telomerase

Older siblings' example turns stem cells into heart cells

Preclinical evaluation of the survivin inhibitor FL-118 in relapsed/refractory multiple myeloma

KCNMB1 methylation increases BK channel activity, resulting in myofibroblast differentiation in IPF

Human recombinant ACE2 blocks the early stages of SARS-CoV-2 infection in cell and tissue models

First patient dosed in proof-of-concept of OTL-201 gene therapy

Phase III VOYAGER study of avapritinib does not meet primary endpoint

Tetra Bio-Pharma to develop PPP-003 for management of CRS

Topline data from phase III study of Dextenza in allergic conjunctivitis

Vicore receives regulatory approval to initiate phase II study of VP-01 in COVID-19

FDA clears IND application for CRX-100

Regenacy Pharmaceuticals discloses new HDAC1/HDAC2 inhibitors

ABBV-951 shows promising safety in patients with Parkinson's disease

Protein binder specific for hPD-1 shows strong antitumor activity in vivo

First prospective peek at Thrive's Cancerseek reveals gaps in liquid biopsy testing

Interim phase I data for ATOR-1015 presented by Alligator Bioscience

New thyroid hormone receptor beta agonists synthesized at Inventisbio Shanghai

FORMA Therapeutics describes new FAS inhibitors

New glucocorticoid receptor antagonists discovered at ORIC Pharmaceuticals

Sage Therapeutics patents GABA(A) receptor modulators

Innate's avdoralimab studied in phase II trial for patients with COVID-19 and severe pneumonia

Phase II interim results presented for GX-188E + pembrolizumab in HPV-positive cervical cancer

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 8, 2026.
New York University identifies new analogues of mannose-6-phosphate
BioWorld Science
New York University has discovered new analogues of mannose-6-phosphate reported to be potentially useful for the treatment of memory impairment,...
ASCO 2026: Chinese biopharma arrives at ASCO with pivotal wins
BioWorld
If the 2026 American Society of Clinical Oncology (ASCO) annual meeting in Chicago from May 30 to June 3 demonstrated anything about the evolution of China’s...
Bial-Portela discovers new OX1 receptor antagonists
BioWorld Science
Bial-Portela & Ca SA has patented new orexin OX1 receptor antagonists potentially useful for the treatment of anxiety disorders, depression, eating disorders,...
FB-7033 demonstrates efficacy in MASH management
BioWorld Science
17-β-Hydroxysteroid dehydrogenase 13 (HSD17B13) and lipid transferase CIDEB are known to contribute to metabolic dysfunction-associated steatohepatitis (MASH)...